Regenerative Medical Technology (RMTG) Change in Receivables (2021 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Change in Receivables of -$8994.0 for Q1 2026, down 42.78% year-over-year from -$15719.5 in Q1 2025, and up 87.19% quarter-over-quarter from -$70191.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Change in Receivables (2021 - 2026) Analysis & Trends
Regenerative Medical Technology's Change in Receivables history runs 6 years deep, the most recent figure standing at -$8994.0 for Q1 2026.
- In Q1 2026, Change in Receivables fell 42.78% year-over-year to -$8994.0; the TTM figure through Mar 2026 stood at $18515.0 (up 168.07% YoY), while the FY2025 annual figure was $21210.0, up 1669.95% from the prior year.
- Change in Receivables for Q1 2026 stood at -$8994.0, up from -$70191.0 in the prior quarter.
- The five-year high for Change in Receivables was $77330.0 in Q3 2025, with the low at -$70191.0 in Q4 2025.
- The 5-year median for Change in Receivables is -$8401.0 (2024), against an average of $1033.2.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables tumbled 1329.01% in 2022, then jumped 1034.2% in 2025.
- Regenerative Medical Technology's Change in Receivables stood at -$36497.0 in 2022, then surged by 69.71% to -$11055.0 in 2023, then advanced by 24.01% to -$8401.0 in 2024, then plunged by 735.51% to -$70191.0 in 2025, then soared by 87.19% to -$8994.0 in 2026.
- Business Quant data shows RMTG's Change in Receivables at -$8994.0 in Q1 2026, -$70191.0 in Q4 2025, and $77330.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | -8,994.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,994.00 |
| Mar 31, 2026 | -8,994.00 |
| Dec 31, 2025 | -70,191.00 |
| Dec 31, 2025 | -70,191.00 |
| Sep 30, 2025 | 77,330.00 |
| Sep 30, 2025 | 77,330.00 |
| Jun 30, 2025 | 20,370.00 |
| Jun 30, 2025 | 20,370.00 |
| Mar 31, 2025 | -6,299.00 |
| Mar 31, 2025 | -6,299.00 |
| Dec 31, 2024 | -8,401.00 |
| Dec 31, 2024 | -8,401.00 |
| Sep 30, 2024 | 6,818.00 |
| Sep 30, 2024 | 6,818.00 |
| Jun 30, 2024 | -19,318.00 |
| Jun 30, 2024 | -19,318.00 |
| Mar 31, 2024 | 19,550.00 |
| Mar 31, 2024 | 19,550.00 |
| Dec 31, 2023 | -11,055.00 |
| Dec 31, 2023 | -11,055.00 |